Regeneron Pharmaceuticals and Sanofi have announced promising outcomes from the open-label Phase IV DISCOVER trial of ...

A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in ...

Dupilumab is a human monoclonal antibody ... was developed by the trial sponsors (Sanofi and Regeneron Pharmaceuticals) and three of the authors. Data were collected by the investigators and ...

French pharma major Sanofi and US partner Regeneron Pharmaceuticals yesterday presented positive results from the EVEREST ...

These are the first clinical study results for the drug in a large population of patients with darker skin tones ...

Confirming the results of Study A, this second pivotal trial in biologic-naïve patients met primary and key secondary endpoints, showing treatment with Dupixent resulted in a nearly 50% ...

Sanofi and Regeneron said that drug candidate Itepekimab didn’t meet primary endpoint in a phase three study, although a ...

TARRYTOWN, N.Y. and PARIS, June 07, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented results from the DISCOVER Phase 4, single-arm, open-label ...

Sanofi and Regeneron have reported that the Phase III AERIFY-1 trial of the fully human monoclonal antibody itepekimab in former smokers who have inadequately controlled chronic obstructive ...

Data from prior Sanofi/Regeneron studies further supports ... on high-dose ICS plus placebo. The VESTIGE trial, meanwhile, demonstrated that dupilumab led to reductions in mucus plugging and ...

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than 300,000 adults and adolescents aged 12 years and ...